STUMBL Score as a Risk Stratification Tool for Management of Blunt Chest Trauma Patients
Launched by ASSIUT UNIVERSITY · Mar 14, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the STUMBL score, a tool that helps doctors assess the risk of complications in patients with blunt chest injuries. The goal is to see how well this score can predict which patients are more likely to experience serious health issues, such as needing to stay in the intensive care unit (ICU) or facing a higher risk of death. The study will take place in two hospitals in Egypt and aims to focus on patients who have sustained blunt chest trauma but do not have life-threatening conditions or other major injuries.
To participate in this trial, individuals must be 18 years or older and have a blunt chest injury. Unfortunately, those under 18 or with life-threatening conditions will not be eligible. The study is currently not recruiting participants yet, so those interested will need to wait for further announcements. Throughout the trial, participants can expect to receive careful monitoring and evaluation to help doctors understand how well the STUMBL score works in predicting outcomes for patients with similar injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The present study will be conducted on patients of blunt chest trauma of both genders "without intently selected certain gender" and had 18 years old or more.
- Exclusion Criteria:
- • patients \<18 years of age
- • patients with life threatening conditions
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported